REGENXBIO Inc. (RGNX): Price and Financial Metrics

REGENXBIO Inc. (RGNX): $42.32

-1.16 (-2.67%)

POWR Rating

Component Grades













Add RGNX to Watchlist
Sign Up

Industry: Biotech


of 505

in industry


  • Value is the dimension where RGNX ranks best; there it ranks ahead of 68.97% of US stocks.
  • RGNX's strongest trending metric is Growth; it's been moving down over the last 48 weeks.
  • RGNX ranks lowest in Momentum; there it ranks in the 5th percentile.

RGNX Stock Summary

  • Of note is the ratio of REGENXBIO Inc's sales and general administrative expense to its total operating expenses; merely 13.43% of US stocks have a lower such ratio.
  • With a year-over-year growth in debt of 732.76%, REGENXBIO Inc's debt growth rate surpasses 98.16% of about US stocks.
  • Revenue growth over the past 12 months for REGENXBIO Inc comes in at 165.79%, a number that bests 95.59% of the US stocks we're tracking.
  • Stocks that are quantitatively similar to RGNX, based on their financial statements, market capitalization, and price volatility, are RARE, EDIT, SLDB, MTEM, and DRNA.
  • RGNX's SEC filings can be seen here. And to visit REGENXBIO Inc's official web site, go to

RGNX Valuation Summary

  • RGNX's EV/EBIT ratio is -9.6; this is 132.76% lower than that of the median Healthcare stock.
  • Over the past 72 months, RGNX's EV/EBIT ratio has gone up 37.2.
  • RGNX's price/sales ratio has moved down 197.3 over the prior 72 months.

Below are key valuation metrics over time for RGNX.

Stock Date P/S P/B P/E EV/EBIT
RGNX 2021-08-31 8.5 2.7 -9.5 -9.6
RGNX 2021-08-30 8.4 2.7 -9.3 -9.4
RGNX 2021-08-27 8.5 2.7 -9.4 -9.5
RGNX 2021-08-26 8.2 2.6 -9.2 -9.2
RGNX 2021-08-25 8.3 2.7 -9.3 -9.3
RGNX 2021-08-24 8.4 2.7 -9.3 -9.3

RGNX's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • RGNX has a Quality Grade of D, ranking ahead of 19.16% of graded US stocks.
  • RGNX's asset turnover comes in at 0.218 -- ranking 190th of 677 Pharmaceutical Products stocks.
  • PTGX, MRTX, and MRK are the stocks whose asset turnover ratios are most correlated with RGNX.

The table below shows RGNX's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.218 0.738 -0.257
2021-03-31 0.242 0.762 -0.255
2020-12-31 0.286 0.769 -0.281
2020-09-30 0.297 0.798 -0.244
2020-06-30 0.126 0.763 -0.367
2020-03-31 0.104 0.776 -0.257

RGNX Price Target

For more insight on analysts targets of RGNX, see our RGNX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $64.00 Average Broker Recommendation 1.5 (Moderate Buy)

RGNX Stock Price Chart Interactive Chart >

Price chart for RGNX

RGNX Price/Volume Stats

Current price $42.32 52-week high $50.26
Prev. close $43.48 52-week low $26.40
Day low $42.22 Volume 249,600
Day high $43.49 Avg. volume 406,737
50-day MA $35.10 Dividend yield N/A
200-day MA $38.50 Market Cap 1.80B

REGENXBIO Inc. (RGNX) Company Bio

REGENXBIO is a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy. The company was founded in 2009 and is based in Rockville, Maryland.

RGNX Latest News Stream

Event/Time News Detail
Loading, please wait...

RGNX Latest Social Stream

Loading social stream, please wait...

View Full RGNX Social Stream

Latest RGNX News From Around the Web

Below are the latest news stories about REGENXBIO Inc that investors may wish to consider to help them evaluate RGNX as an investment opportunity.

Pharma Stock Roundup: ABBV's Deal With RGNX, LLY COVID Drug's Government Order Win

AbbVie (ABBV) buys rights to Regenexbio's gene therapy candidate for chronic retinal diseases. Lilly (LLY) will supply additional doses of its COVID-19 antibody medicine to the U.S. government.

Yahoo | September 17, 2021

AbbVie, RegenXBio Partner for Wet AMD, DR Treatment

Illinois-based biopharmaceutical company AbbVie (ABBV) and Maryland-based biotechnology firm RegenXBio (RGNX) have partnered for the development and sale of RGX-314, a novel one-time gene therapy for wet age-related macular degeneration (AMD), diabetic retinopathy (DR) and other chronic retinal diseases. Following the announcement of the news, RegenXBio’s shares jumped 31.2% to close at $43.40 on Monday. However, the shares slipped 1.2%, at the time of writing, in early trade on Tuesday. (See RegenXBio stock chart on TipRanks) Currently, RGX-314 is being evaluated in two separate Phase II clinical trials in patients with wet AMD and DR and in a pivotal trial in patients with wet AMD.

Richika Biyani on TipRanks | September 14, 2021

REGENXBIO (RGNX) Stock Up on Collaboration Deal With AbbVie

REGENXBIO (RGNX) enters into a strategic partnership with AbbVie to co-develop and commercialize RGX-314, a potential gene therapy for retinal indications. Resultantly, REGENXBIO's share price surges.

Yahoo | September 14, 2021

AbbVie (ABBV) to Co-Develop Regenxbio Eye Disease Gene Therapy

AbbVie (ABBV) is set to co-develop Regenexbio's investigational gene therapy for chronic retinal diseases like wet age-related macular degeneration.

Yahoo | September 14, 2021

5 Gene Therapy Stocks Back in Focus on AbbVie/Regenxbio Deal

The promising gene therapy approach is being evaluated for varied diseases, such as hemophilia, Duchenne muscular dystrophy (DMD), Parkinson's disease, eye disease, and cancer among others

Yahoo | September 14, 2021

Read More 'RGNX' Stories Here

RGNX Price Returns

1-mo 35.64%
3-mo 4.55%
6-mo 25.77%
1-year 51.96%
3-year -43.35%
5-year 189.47%
YTD -6.70%
2020 10.72%
2019 -2.34%
2018 26.17%
2017 79.25%
2016 11.75%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 1.2361 seconds.